Abstract
A feasible method to detect somatic copy number deletion (SCND) of tumor suppressor genes is still absent up to date. To overcome the obstacle of SCND detection, we analyzed genomic coordinates of gene deletion fragments using the Catalogue Of Somatic Mutation In Cancer (COSMIC) datasets. Interstitial base-resolution deletion/fusion coordinates for CDKN2A were extracted from published articles and our whole genome sequencing (WGS) datasets. The results showed that estimated common deletion regions (CDRs) were observed in many tumor suppressor genes, such as ATM, CDKN2A, FAT1, miR31HG, PTEN, and RB1 in the SNP array-based COSMIC datasets. A 5.1-kb base-resolution CDR could be identified in >90% cancer samples by sequencing. Using the true CDKN2A CDR as a PCR target, a multiplex quantitative PCR assay P16-Light was programmed to detect CDKN2A gene copy number with a lower detection limit of 20%. P16-Light was further confirmed with WGS as the gold standard among cancer tissue samples from 139 patients. In conclusion, CDRs are common in many tumor suppressor genes. The 5.1-kb CDKN2A CDR was found in >90% cancers containing CDKN2A deletion. The CDKN2A CDR was used a potential target for developing the P16-Light assay to detect CDKN2A SCND and amplification for routine clinical practices.
Competing Interest Statement
DD, YT, JZ, and ZL are the creators for the pending patent "A quantitative method for detection of human CDKN2A gene copy number using a primer set and their applications" (PCT/CN2019/087172; WO2020228009).
Funding Statement
This work was supported by the Beijing Natural Science Foundation (grant number 7181002 to D.J.D.); Capital's Funds for Health Improvement and Research (grant number 2018-1-1021 to D.J.D.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institution Review Board of Peking University Cancer Hospital & Institute approved this study and was carried out in accordance with the principles outlined in the Declaration of Helsinki. Informed consent was obtained from each patient prior to their inclusion in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We updated the manuscript. The main changes are summarized below. 1. Although we provided a novel assay P16-Light for clinical lab, to emphasize the prevalence of gene-specific common deletion region (CDR) within tumor suppressor genes, the paper title and first paragraph of the Result Section were changed. And Figure 2 was added. This may increase common interest of the genetics community. 2. A previously reported assay (P14-qPCR, Ref.15) was used to increase the coverage of CDKN2A deletion fragments not overlapped with the CDKN2A CDR (from 86% to 98%). The performance of P14-qPCR and P16-Light was also compared using gastric carcinoma and paired surgical margin samples from 139 patients. 3. The purity of gastric cancer samples was calculated using the WGS data. No significant difference in the purity was observed between gastric cancer samples with different states of CDKN2A SCNVs. 4. The results of MSI analysis were deleted. 5. The sentence “These phenomena suggest that both inherited and somatic defects of the CDKN2A CDR region should be cancer drivers.” was deleted. To show the overlap status of the CDKN2A CDR with the OMIN data, we kept other sentences and the Figure S3 in the updated manuscript.
Data Availability
Detailed information on the base-resolution interstitial common deletion region in the CDKN2A gene in 110 cancer samples and other data were provided in Supplementary Data files 1-14.
Abbreviations
- CDR
- common deletion region
- DHPLC
- denaturing high performance liquid chromatography
- GC
- gastric carcinoma
- LOH
- loss of heterozygosity
- MSI
- microsatellite instability
- OMIM
- the Online Mendelian Inheritance in Man
- SCND
- somatic copy number deletion
- SM
- surgical margin
- TCGA
- The Cancer Genome Atlas
- WGS
- whole genome sequencing